GENERIC ONCOLOGY STERILE INJECTABLES MARKET ANALYSIS

Generic Oncology Sterile Injectables Market, by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Jan 2020
Code : CMI562
Pages :151
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Generic Oncology Sterile injectables Market - Regional Insights

On the basis of region, the global generic oncology sterile injectables market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the global generic oncology sterile injectables market, owing to increasing launches of products in the U.S. For instance, in September 2019, Mylan N.V. launched Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex Injection, for the treatment of advanced breast cancer in the U.S.

Asia Pacific is the fastest growing region in the global generic oncology sterile injectables market, owing to increasing initiatives taken by key players in this region. For instance, in 2017, Alembic Pharmaceutical Limited launched manufacturing facility in India to manufacture generic oncology products for international market.